|
|
Vol. 24.26 – 31 July, 2023
|
|
|
|
|
|
|
|
Researchers combined lipid nanoparticle–mRNA formulations and dendritic cell therapy to boost the cancer–immunity cycle via progressive steps to overcome the immunosuppressive tumor microenvironment. [Nature Nanotechnology]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
The rational design and combinatorial synthesis of esterase-triggered decationizable quaternium lipid-like molecules was reported to develop new lipid nanoparticles with high delivery efficiency and improved storage stability.
[Advanced Materials]
|
|
|
|
|
|
Researchers tested the ability of growth arrest-specific protein 6 (GAS6) based CAR-T-cell to kill pancreatic cancer cell both in vitro and in vivo, and futher evaluated its safety in mice and nonhuman primates.
[Journal of Hematology & Oncology]
|
|
|
|
|
|
Investigators developed an all-in-one biomimetic mineralized CRISPR/Cas9 RNA delivery system, that allowed for precise control over the coencapsulation ratio between Cas9 mRNA and multiple sgRNAs, while also exhibiting a high RNA loading capacity.
[ACS Nano]
|
|
|
|
|
|
Scientists performed single-cell RNA sequencing and mass cytometry to study the heterogeneity of CAR-natural killer (NK) cells and their in vivo evolution after adoptive transfer, from the phase of tumor control to relapse.
[Science Advances]
|
|
|
|
|
|
Researchers explored whether flap structure-specific endonuclease 1 (FEN1) inhibitors combined with CAR-T-cell immunotherapy would have a stronger killing effect on solid tumors.
[Immunology]
|
|
|
|
|
|
Investigators demonstrated that nanobody-derived bispecific CAR-T cells significantly improved anti-tumor efficacy in T-lymphoma treatment.
[Molecular Therapy Oncolytics]
|
|
|
|
|
|
In vivo efficacy and safety studies using NSG mice and the high-grade serous ovarian cancer cell line OVCAR4 demonstrated a remarkable and specific anti-tumor response at all the CAR-T cell doses used.
[Molecular Cancer Therapeutics]
|
|
|
|
|
|
The authors investigated whether a novel bioabsorbable gelatin hydrogel nonwoven fabric could improve subcutaneous islet engraftment. [Scientific Reports]
|
|
|
|
|
|
|
|
Scientists review the rationale behind CAR T therapy, current challenges faced in oncology, a synopsis of preliminary reports in noncancerous diseases, and a discussion of relevant emerging technologies.
[Nature]
|
|
|
|
|
|
Investigators present the state of the art of cell-based therapy in chronic obstructive pulmonary disease (COPD) and discuss clinical trials that have been completed and published. [European Respiratory Review]
|
|
|
|
|
|
|
|
Invectys, Inc. announced the US FDA has granted Fast Track designation to its revolutionary product, IVS-3001, a CAR-T cell immunotherapy that targets the rarely exploited immune checkpoint and tumor-specific antigen known as HLA-G.
[Invectys, Inc.]
|
|
|
|
|
|
Citius Pharmaceuticals, Inc. announced that the US FDA has issued a Complete Response Letter regarding the Company’s Biologics License Application seeking approval for denileukin diftitox. [Citius Pharmaceuticals, Inc.]
|
|
|
|
|
|
|
|
September 4 – 7, 2023 Surrey, England, United Kingdom
|
|
|
|
|
|
|
|
|
|
|
IRB Barcelona – Barcelona, Spain
|
|
|
|
|
|
|
Harvard Medical School-Brigham and Women’s Hospital – Boston, Massachusetts, United States
|
|
|
|
|
|
|
NCI Center for Cancer Research – Bethesda, Maryland, United States
|
|
|
|
|
|
|
University of Cincinnati – Cincinnati, Ohio, United States
|
|
|
|
|
|
|
NICHD – Bethesda, Maryland, United States
|
|
|
|
|
|